Oregon Public Employees Retirement Fund Acquires 34,235 Shares of Gilead Sciences, Inc. $GILD

Oregon Public Employees Retirement Fund increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 31.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 141,776 shares of the biopharmaceutical company’s stock after purchasing an additional 34,235 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in Gilead Sciences were worth $15,737,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of the business. GoalVest Advisory LLC boosted its holdings in shares of Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares during the last quarter. Harbor Asset Planning Inc. bought a new position in Gilead Sciences during the second quarter valued at approximately $27,000. Putney Financial Group LLC boosted its holdings in Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 94 shares during the last quarter. Howard Hughes Medical Institute bought a new stake in Gilead Sciences in the 2nd quarter worth approximately $30,000. Finally, Kilter Group LLC purchased a new stake in Gilead Sciences during the 2nd quarter valued at $33,000. 83.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Citigroup raised their price target on Gilead Sciences from $135.00 to $140.00 and gave the stock a “buy” rating in a research note on Wednesday. Wall Street Zen raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 3rd. Daiwa Capital Markets upped their price target on shares of Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a research report on Thursday, November 13th. The Goldman Sachs Group raised their price objective on shares of Gilead Sciences from $108.00 to $110.00 and gave the stock a “neutral” rating in a report on Friday, October 31st. Finally, Sanford C. Bernstein set a $135.00 target price on shares of Gilead Sciences and gave the company an “outperform” rating in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $133.20.

Gilead Sciences Trading Up 0.4%

Shares of NASDAQ:GILD opened at $121.10 on Friday. The stock has a 50 day moving average of $123.27 and a 200 day moving average of $117.51. The company has a market cap of $150.25 billion, a PE ratio of 18.78, a price-to-earnings-growth ratio of 0.64 and a beta of 0.33. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a 12-month low of $88.57 and a 12-month high of $128.70.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm’s revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the business earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 30th. Investors of record on Monday, December 15th were paid a dividend of $0.79 per share. The ex-dividend date was Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. Gilead Sciences’s payout ratio is 48.99%.

Insider Buying and Selling

In other news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $125.86, for a total value of $3,524,080.00. Following the completion of the transaction, the insider owned 107,193 shares of the company’s stock, valued at $13,491,310.98. This represents a 20.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $122.00, for a total value of $366,000.00. Following the sale, the chief financial officer directly owned 153,503 shares in the company, valued at $18,727,366. This trade represents a 1.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 136,257 shares of company stock worth $16,855,192 in the last three months. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.